Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer-Real World Outcomes After Two Years of Therapy (COPILOT).

Background: Seminal trials with first-line pembrolizumab for metastatic non-small cell lung cancer (NSCLC) mandated a maximum two-years treatment. We describe real-world outcomes of a multi-site Australian cohort of patients who completed two-years of pembrolizumab.

Methods: Retrospective data were collected from the national AUstralian Registry and biObank of thoRacic cAncers (AURORA).

The impact of an educational and information systems initiative on somatic testing rates in patients with high grade serous tubo-ovarian cancer in Western Australia.

Objective: Poly-ADP ribose polymerase inhibitors (PARPi) have expanded the management armamentarium against high grade serous tubo-ovarian cancer (HGSOC) in patients with germline and somatic pathogenic variants (PVs). Germline testing has been available in Western Australia (WA) since July 2015, whilst somatic testing was previously only available through interstate laboratories. We hypothesized that due to complexity of referral, testing rates for somatic would be low.